Category: Herbs & Ingredients
A recurring complaint about ashwagandha is that it leaves some users feeling emotionally flat rather than calm. No clinical trial has ever measured emotional blunting as an outcome, so the honest answer sits between mechanism and anecdote. Here is what each side actually supports.
Category: Herbs and Ingredients | Reading time: ~12 min | Level: Intermediate
There is a specific complaint that keeps surfacing about ashwagandha, and it is worth taking seriously because it does not sound like the usual supplement grumble. People do not say it stopped working. They say it worked too well in the wrong direction. The stress went quiet, and so did everything else. One person describes feeling settled but strangely far away from their own reactions. Another says they no longer get anxious, but they no longer get excited either. The word that comes up again and again is flat.
This is a harder question than it looks, and most articles answer it badly in one of two ways. The credulous version waves it off as rare and moves on to selling the benefits. The alarmist version treats a handful of forum posts as a proven pharmacological effect. Neither is honest. The truthful position is that emotional blunting from ashwagandha has never been measured in a clinical trial, and that this absence is the most important fact in the whole discussion. What follows is an attempt to hold both things at once: the reports are real, and the evidence for them is thin.
If you have felt flat on ashwagandha and want to know whether that was the supplement, whether it will last, and what to do about it, this is written for you.
Emotional blunting is a reduction in the intensity of feelings across the board, both the good and the bad. It is not the same as sadness. A person who is sad still feels strongly. A person who is blunted feels less of everything: less anxiety, but also less joy, less motivation, and a sense of watching their own life from a slight distance. The term is used most often in the context of antidepressants, where it is a recognised and measured phenomenon [4].
That distinction matters for ashwagandha, because the intended effect of ashwagandha is not blunting. The effect people report positively is feeling less reactive to stress while still feeling like themselves: the argument that lands, the deadline that looms, the difficult conversation, all of it lands with less physiological alarm. Blunting is when that dial goes too far and takes the colour out with the noise. Telling the two apart is the whole practical question here.
Start with what ashwagandha is genuinely evidenced for, because that frames everything else. Its strongest use is stress. Reviewing bodies and meta-analyses report a measurable reduction in stress markers and self-reported stress, and the most cited early trial found a meaningful drop in cortisol over 60 days [1][2]. That effect is real, but it is best graded as moderate rather than strong, because trial quality and the way ashwagandha is standardised vary a great deal between studies [1].
For anxiety and mood specifically, the evidence is weaker. The US National Center for Complementary and Integrative Health describes the evidence for anxiety as unclear, and a 2024 systematic review concluded that the evidence remains limited [1][3]. That is the honest grade. Ashwagandha is not an established mood medicine, and it should not be discussed as one.
Now the key point about blunting. Across this literature, the outcomes that were measured are stress scales, cortisol, anxiety questionnaires, and sleep. No trial set out to measure emotional blunting, apathy, or a loss of positive feeling. This is not a case of studies looking and finding nothing. It is a case of studies not looking at all. So when someone asks whether ashwagandha causes emotional blunting, the accurate answer is that no one has tested the question in a controlled way, and the reports we have are anecdotal. Anecdote is not nothing, but it is not a trial result, and it should not be dressed up as one.
People often reach for the antidepressant comparison, and it is a reasonable instinct, but the mechanisms do not obviously line up. Antidepressant-related emotional blunting has been studied directly. In one survey of depressed patients on treatment, close to half reported some degree of emotional blunting, and the effect was seen across drug classes that share a serotonergic action [4]. The leading explanation ties the blunting to sustained serotonin activity altering how the emotional-regulation circuits of the frontal brain behave [4].
Ashwagandha is not thought to work that way. Its proposed mechanisms centre on calming the stress axis, the HPA axis, through its withanolide compounds, together with mild activity at GABA, the brain's main calming signal [1]. Neither of those is the serotonin pathway most associated with antidepressant blunting. So the popular shorthand that ashwagandha blunts emotions the way an SSRI does is an assumption built on a surface resemblance, not a demonstrated shared mechanism.
There is a more mundane explanation that fits the reports at least as well: sedation. Ashwagandha is calming, and at a higher dose, or taken at the wrong time, that calm can present as feeling dulled, heavy, or detached, especially in someone who is also short on sleep or run down. Sedation and blunting can feel similar from the inside. The difference is that sedation tracks with dose and timing, and it lifts when you change them. That is a testable difference, and it is the first thing to check.
If ashwagandha leaves you feeling flat rather than settled, treat it as a signal, not a stage to push through. A few practical moves, in order.
First, look at dose. Trials use standardised extracts, most often in the range of 300 to 600mg of a standardised extract per day, and some show effects at lower doses of 120 to 240mg [1][2]. If you are at the top of that range or above it, drop down. The dulled feeling frequently eases at a lower dose while the calming benefit stays.
Second, look at timing. Because the sedating quality is part of the picture, weighting more of the dose to the evening keeps the calm working when you want it, at night, and off the daytime hours when you need to feel engaged.
Third, give it a deliberate pause. Ashwagandha acts while you take it and tapers after you stop, and there is no evidence of a lasting change in emotional range once it clears [1]. A short, clean break, with everything else in your routine held steady, is the single best way to find out whether the supplement is responsible. If the flatness lifts off the supplement and returns on it, you have your answer.
Fourth, separate the supplement from the reason you took it. Chronic stress and disrupted sleep flatten mood on their own. If your mood was already low before ashwagandha, the herb is unlikely to be the whole story, and that is a conversation for a clinician rather than a dosing tweak.
One thing not to do: do not chase a numb feeling as proof of effect. Feeling nothing is not the goal and is not a marker that the supplement is working.
Because the reports lump together several different experiences under the word flat, it helps to separate them, since the right response differs for each.
Sedation is a heaviness or drowsiness, a sense of being slowed down. It tends to track closely with dose and timing, is often worst a couple of hours after a dose, and eases when you lower the dose or shift it later in the day. If your flat feeling comes with sleepiness and responds to those changes, sedation is the most likely explanation, and it is the easiest to fix.
Blunting proper is different. It is not sleepiness but a narrowing of feeling: things that used to move you, good and bad, land softer. You are alert but muted. This is the experience that most resembles what is described on antidepressants, and it is the one for which ashwagandha has no trial evidence either way [1][4]. If lowering the dose does not restore the colour, a deliberate pause is the cleanest test.
A third possibility is that the flatness is not the supplement at all. Chronic stress, poor sleep, and low mood all flatten emotional range on their own, and if any of those predate the ashwagandha, the herb may be a bystander [1]. A low mood that is persistent, comes with loss of interest, or was present before you started supplementing is a reason to speak to a clinician rather than to keep adjusting a capsule.
Naming which of the three you are experiencing is most of the work. Sedation points to dose and timing, blunting points to a pause and reassessment, and a pre-existing low mood points to a clinician. Trying to fix the wrong one is why people spend months adjusting a supplement that was never the cause.
Honesty about the limits of the evidence is the point of this article, so it is worth stating the gaps plainly rather than papering over them.
No trial has measured emotional blunting, apathy, or loss of positive feeling as an outcome for ashwagandha, so there is no reliable figure for how common it is, who is prone to it, or at what dose it appears [1]. Everything on that specific question is inference from mechanism and inference from anecdote, and both have real limits. Mechanism can mislead, because a plausible pathway does not guarantee a real-world effect. Anecdote can mislead too, because people who feel flat are far more likely to post about it than people who feel fine, which inflates how common a problem looks online.
What we can say with more confidence is the shape of the answer. Ashwagandha is slow, dose-sensitive, and calming, so a dulled feeling is more consistent with sedation or an overshoot of the intended calm than with a distinct blunting mechanism, though the latter cannot be ruled out [1][2]. The intended effect is feeling less reactive while still feeling like yourself, and numbness is a departure from that, not a version of it. Until someone runs a trial that actually measures the outcome, that is the honest ceiling on what can be claimed in either direction, and anyone stating it more firmly than that is going beyond the evidence.
Blunting is not the only reason to use ashwagandha carefully, and the safety picture deserves its own heading rather than a footnote.
The most important recent development is the liver signal. The US LiverTox database assigns ashwagandha a likelihood score indicating it is a probable cause of clinically apparent liver injury, typically appearing within a few weeks to a few months of starting and usually resolving after stopping, with rare severe cases [5]. Anyone with existing liver disease should avoid it, and warning signs such as unusual fatigue, nausea, poor appetite, dark urine, or yellowing of the skin or eyes are reasons to stop and seek advice [5].
Beyond the liver, several firm cautions apply. Ashwagandha is not recommended in pregnancy or breastfeeding, and it is generally advised against in thyroid disorders and autoimmune conditions because of its effects on thyroid hormones and immune activity [1][5]. It may add to the effect of sedatives, and reviewing bodies flag caution alongside thyroid medicines, immune-suppressing drugs, sedatives, seizure medicines, and blood sugar and blood pressure medicines [1]. Short-term use of up to around three months is considered possibly safe; longer-term use is not well studied [1].
Pregnant, breastfeeding, or on medication? Check with a healthcare professional first.
Ashwagandha is a genuinely useful botanical for the right person and the wrong choice for others, and the difference is in how carefully it is used rather than in hype. If you are exploring it for stress, the Ashwagandha Stress Tonic in the Remedy Library is presented with its studied dose range and its cautions attached, which is the register this ingredient deserves: an adaptogen with moderate evidence for stress, not a mood cure. Structure and function only. It supports the body's stress response; it does not treat a mood disorder, and it should never be used to self-manage one.
If the flat feeling is what brought you here, the most valuable step is not a different product but a clear read on cause. Remy, the PlantRx assistant, can walk you through the dose-and-timing checks above and flag the contraindications that apply to you before you decide whether to continue, lower, or stop.
1. National Center for Complementary and Integrative Health (NCCIH). Ashwagandha: Usefulness and Safety. Government evidence and safety review. nccih.nih.gov/health/ashwagandha. 2. Chandrasekhar K, et al. (2012). A prospective, randomized double-blind, placebo-controlled study of ashwagandha root in reducing stress and anxiety. Indian Journal of Psychological Medicine. RCT, 64 chronically stressed adults, 60 days. 3. Systematic review (2024), Human Psychopharmacology (PMID 39083548), which characterised the evidence for ashwagandha in anxiety and stress as limited. 4. Goodwin GM, Price J, Bodinat C, Laredo J (2017). Emotional blunting with antidepressant treatments: a survey among depressed patients. Journal of Affective Disorders. Cross-sectional survey of depressed patients, cited here to characterise antidepressant-related blunting, not ashwagandha. 5. National Institute of Diabetes and Digestive and Kidney Diseases, LiverTox. Ashwagandha (NBK548536). Government safety monograph.
Some people report exactly that, and those reports are consistent enough to take seriously. What does not exist is a clinical trial that set out to measure emotional blunting with ashwagandha, so the effect is documented as user experience rather than as a trial finding. If you feel dulled rather than calmed, that is a signal to lower the dose or stop, not to push through.
Probably not, because the mechanisms differ. Antidepressant-related emotional blunting is linked to sustained serotonin activity, and it has been measured in surveys of people on SSRIs. Ashwagandha is thought to work mainly through the stress axis and mild GABA activity, not by raising serotonin, so grouping the two together is an assumption rather than a demonstrated fact.
The most common practical explanations are dose and timing. Ashwagandha is calming, and at a higher dose or the wrong time of day that calm can tip into feeling dulled or sedated. Shifting more of the dose to the evening, or reducing it, resolves this for many people. If it does not, stopping is reasonable.
The effects of ashwagandha are active while you take it and taper after you stop. There is no evidence of a lasting change in emotional range from stopping ashwagandha. If a low or flat mood persists well after stopping, that points to something other than the supplement and is worth discussing with a clinician.
Ashwagandha is slow. The stress and cortisol changes measured in trials emerge over weeks, not days. A feeling of flatness within a day or two is more likely to be sedation from the dose than a stress-axis effect, which is another reason to look at dose and timing first.
No. A blunted or numb feeling is not the intended effect and is not a marker of benefit. The effect people describe positively is feeling less reactive to stress while still feeling like themselves. Numbness is a reason to reassess, not to continue.
A drop in drive alongside the calm is one of the more common informal reports, though it has not been measured in a trial. Because ashwagandha is slow and dose-sensitive, the sensible first move is to reduce the dose and see whether the calm stays while the flatness lifts. If motivation stays low, stopping and reassessing is reasonable, and worth mentioning to your clinician if your mood was already low.
Both are possible and they are hard to separate without changing one variable at a time. Chronic stress and poor sleep flatten mood on their own. A short, deliberate pause from the supplement, with everything else held steady, is the cleanest way to see which is doing what. If low mood predates the ashwagandha, that is a conversation for a clinician rather than a supplement question.
There is no trial comparing forms for this specific effect, so any answer is inference. Lower doses within the studied range and evening-weighted timing are the levers with the most logic behind them, because the dulled feeling tracks with sedation. Standardised root extracts are the ones with trial data behind their dosing, unlike generic powder.